BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 26032155)

  • 41. Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% Accuracy.
    Modlin IM; Kidd M; Frilling A; Falconi M; Filosso PL; Malczewska A; Kitz A
    Ann Surg; 2021 Sep; 274(3):481-490. PubMed ID: 34183517
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Blood mRNA Measurement (NETest) for Neuroendocrine Tumor Diagnosis of Image-Negative Liver Metastatic Disease.
    Malczewska A; Bodei L; Kidd M; Modlin IM
    J Clin Endocrinol Metab; 2019 Mar; 104(3):867-872. PubMed ID: 30358858
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.
    Hijioka M; Ito T; Igarashi H; Fujimori N; Lee L; Nakamura T; Jensen RT; Takayanagi R
    Cancer Sci; 2014 Nov; 105(11):1464-71. PubMed ID: 25220535
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
    Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
    Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical usefulness of plasma chromogranin a in pancreatic neuroendocrine neoplasm.
    Paik WH; Ryu JK; Song BJ; Kim J; Park JK; Kim YT; Yoon YB
    J Korean Med Sci; 2013 May; 28(5):750-4. PubMed ID: 23678268
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors.
    Malczewska A; Kos-Kudła B; Kidd M; Drozdov I; Bodei L; Matar S; Oberg K; Modlin IM
    Adv Med Sci; 2020 Mar; 65(1):18-29. PubMed ID: 31841822
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Blood Transcript Profiling for the Detection of Neuroendocrine Tumors: Results of a Large Independent Validation Study.
    van Treijen MJC; Korse CM; van Leeuwaarde RS; Saveur LJ; Vriens MR; Verbeek WHM; Tesselaar MET; Valk GD
    Front Endocrinol (Lausanne); 2018; 9():740. PubMed ID: 30564197
    [No Abstract]   [Full Text] [Related]  

  • 48. The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors.
    Kim M; Lee S; Lee J; Park SH; Park JO; Park YS; Kang WK; Kim ST
    Cancer Res Treat; 2016 Jan; 48(1):153-61. PubMed ID: 25779359
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diagnostic value of chromogranin A in pancreatic neuroendocrine tumors depends on tumor size: A prospective observational study from a single institute.
    Jun E; Kim SC; Song KB; Hwang DW; Lee JH; Shin SH; Hong SM; Park KM; Lee YJ
    Surgery; 2017 Jul; 162(1):120-130. PubMed ID: 28262254
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas.
    Qiao XW; Qiu L; Chen YJ; Meng CT; Sun Z; Bai CM; Zhao DC; Zhang TP; Zhao YP; Song YL; Wang YH; Chen J; Lu CM
    BMC Endocr Disord; 2014 Aug; 14():64. PubMed ID: 25099181
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The clinical utility of circulating neuroendocrine gene transcript analysis in well-differentiated paragangliomas and pheochromocytomas.
    Pęczkowska M; Cwikla J; Kidd M; Lewczuk A; Kolasinska-Ćwikła A; Niec D; Michałowska I; Prejbisz A; Januszewicz A; Chiarelli J; Bodei L; Modlin I
    Eur J Endocrinol; 2017 Feb; 176(2):143-157. PubMed ID: 27913608
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors.
    Pulvirenti A; Rao D; Mcintyre CA; Gonen M; Tang LH; Klimstra DS; Fleisher M; Ramanathan LV; Reidy-Lagunes D; Allen PJ
    HPB (Oxford); 2019 May; 21(5):612-618. PubMed ID: 30366884
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Role of the Acute Octreotide Suppression Test in Detecting Patients with Neuroendocrine Neoplasms.
    Kruljac I; Vičić I; Blaslov K; Kolak Z; Benković M; Kust D; Ladika Davidović B; Tometić G; Penavić I; Dabelić N; Vazdar L; Pavić T; Vrkljan M
    Neuroendocrinology; 2018; 107(3):284-291. PubMed ID: 30114698
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors.
    Chou WC; Chen JS; Hung YS; Hsu JT; Chen TC; Sun CF; Lu CH; Hwang TL
    Anticancer Res; 2014 Oct; 34(10):5661-9. PubMed ID: 25275071
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Chromogranin A and neuroendocrine tumors].
    Díaz Pérez JÁ; Currás Freixes M
    Endocrinol Nutr; 2013; 60(7):386-95. PubMed ID: 23271036
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of Chromogranin A for Monitoring Patients With Pancreatic Neuroendocrine Neoplasms.
    Yu F; Fu J; Zhang C; Wu W; Ai S; Yao X; Meng Q; Huang Y; Lu G; Wang F; Qu W
    Pancreas; 2021 Jul; 50(6):882-889. PubMed ID: 34347728
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plasma Chromogranin A as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma.
    Lee SH; Jo JH; Kim YJ; Lee HS; Chung MJ; Park JY; Bang S; Park SW; Song SY
    Pancreas; 2019; 48(5):662-669. PubMed ID: 31091213
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A.
    Ardill JE; Armstrong L; Smye M; Doherty R; McCance DR; Johnston BT
    QJM; 2016 Feb; 109(2):111-5. PubMed ID: 25979268
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors.
    Stevenson R; Libutti SK; Saif MW
    JOP; 2013 Mar; 14(2):155-7. PubMed ID: 23474561
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study.
    Vezzosi D; Walter T; Laplanche A; Raoul JL; Dromain C; Ruszniewski P; d'Herbomez M; Guigay J; Mitry E; Cadiot G; Leboulleux S; Lombard-Bohas C; Borson-Chazot F; Ducreux M; Baudin E
    Int J Biol Markers; 2011; 26(2):94-101. PubMed ID: 21574156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.